Vitamin D, Related Genes and Breast Cancer Risk

描述(由研究人员提供)：大量实验数据表明，维生素D抑制细胞增殖，诱导分化和凋亡，提示对癌症有保护作用。维生素D的活性代谢物1，25(OH)2D的形成和降解编码的酶存在于正常和癌症乳腺细胞中，维生素D受体也是如此，维生素D受体是维生素D途径的关键媒介。生态学和病例对照研究支持维生素D对乳腺癌的保护作用；然而，前瞻性数据很少。此外，很少有研究测量循环中的25(OH)D，它被认为是维生素D状态的最佳指标，因为它既能捕捉肠道对维生素D的吸收，又能捕捉皮肤中维生素D的产生。我们建议对维生素D途径与乳腺癌风险的关系进行全面研究。由于维生素D影响细胞增殖，这是雌激素增加乳腺癌风险的主要机制，我们还将评估维生素D是否改变了绝经后女性循环中雌二醇与乳腺癌风险的关系。这项研究将是一项嵌套在纽约大学妇女健康研究和瑞典乳房筛查队列两个队列中的病例对照研究。这两个队列具有相似的设计，并前瞻性地收集生物样本。预计在这两个群体中将观察到总计1,995起事件。将为每个病例选择一名(或52岁病例为两名)对照人员(S)，在队列、种族/民族、更年期、年龄和献血日期方面与病例相匹配。除了基线测量外，我们还将在大约50%的匹配集合中评估重复时间点的25(OH)D(25%中的2个样本和25%中的3个样本)。我们还将评估维生素D相关基因(CYP27A1、CYP24A1、DBP、VDR和RXRA)的遗传变异，并评估循环中的25(OH)D和这些基因的变异对乳腺癌风险的联合影响。将在绝经后的配对人群中测量循环中的雌二醇水平。

DESCRIPTION (provided by investigator): A large body of experimental data indicates that vitamin D inhibits cellular proliferation and induces differentiation and apoptosis, suggesting a protective effect against cancer. The enzymes coding for the formation and degradation of 1,25(OH)2D, the active metabolite of vitamin D, are present in both normal and cancer breast cells, as is the vitamin D receptor, a key mediator in the vitamin D pathway. Ecological and case- control studies support a protective role of vitamin D against breast cancer; however, prospective data are sparse. Moreover, few studies have measured circulating 25(OH)D which is considered the best indicator of vitamin D status because it captures both the absorption of vitamin D in the intestine and its production in the skin. We propose to conduct a comprehensive study of the vitamin D pathway in relation to breast cancer risk. Because vitamin D impacts cell proliferation, the main mechanism by which estrogens increase breast cancer risk, we will also assess whether vitamin D modifies the association of circulating estradiol with breast cancer risk in postmenopausal women. The study will be a case-control study nested within two cohorts, the NYU Women's Health Study and the Mammary Screening Cohort in Sweden. These two cohorts have a similar design and collected biological samples prospectively. A total of 1,995 incident cases is expected to be observed within these two cohorts. One (or two for cases d 52 years of age) control(s) will be selected for each case, matching the case on cohort, race/ethnicity, menopausal status, age at, and date of, blood donation. In addition to baseline measurements, we will assess 25(OH)D at repeat points in time in about 50 percent of the matched sets (2 samples in 25 percent and 3 samples in 25 percent). We will also assess genetic variation in vitamin D-related genes (CYP27A1, CYP24A1, DBP, VDR, and RXRA) and evaluate the joint effects of circulating 25(OH)D and variants in these genes on breast cancer risk. Circulating levels of estradiol will be measured in postmenopausal matched sets.